---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-040755"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2023-02-16T23:59:59+00:00"
generated_at: "2026-06-19T09:37:32.476590+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vir Biotechnology names Sung Lee CFO, replacing Howard Horn effective March 27

## Summary
- Sung Lee appointed EVP and CFO effective March 27, 2023; Howard Horn steps down as CFO but remains EVP through April 28.
- Base salary $525K, target bonus 45%, sign-on cash bonus $500K payable on 1-year anniversary, relocation expenses up to ~$460K.
- Equity awards: option for 133K shares and RSUs for 66.5K shares, each vesting over 4 years.
- Lee previously served as CFO at MorphoSys AG and Sangamo; prior roles at Gilead Sciences.
- Severance provides 12 months pay/benefits + full equity acceleration within 12 months post-change-in-control; 9 months pay outside CIC.

## SEC filing metadata
- accession: 0001193125-23-040755
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2023-02-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000119312523040755/0001193125-23-040755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000119312523040755/d382006d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-040755
- JSON: https://secwatch.observer/filing/0001193125-23-040755.json
- Plain text: https://secwatch.observer/filing/0001193125-23-040755.txt

## Key facts
- Executive change
  Sung Lee was appointed as Executive Vice President and Chief Financial Officer at Vir Biotechnology, Inc..
  - Action: appointed
  - Role: Executive Vice President and Chief Financial Officer
  source text: On February 13, 2023, the Board of Directors (the “Board”) of Vir Biotechnology, Inc. (the “Company”) appointed Sung Lee as Executive Vice President and Chief Financial Officer of the Company, effective as of March 27, 2023 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000119312523040755/0001193125-23-040755-index.htm
- Executive change
  Howard Horn changed role as Chief Financial Officer at Vir Biotechnology, Inc..
  - Action: step down
  - Role: Chief Financial Officer
  source text: Howard Horn will step down as Chief Financial Officer of the Company effective upon Mr. Lee’s appointment on the Effective Date, and will remain with Vir as Executive Vice President until April 28, 2023, to assist with the transition.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000119312523040755/0001193125-23-040755-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.